Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of seven systematic review(s)/meta-analysis(es). ^[1-7]
• Vandetanib and other multikinase inhibitors (MKIs), including Cabozantinib, Lenvatinib, and Sorafenib, were associated with changes in glucose and lipid metabolism, with elevated glucose levels observed in 1-17% of cases, hypercholesterolemia in 4-40%, and hypertriglyceridemia in 1-86%.
• Among 13 treatments for radioiodine-refractory differentiated thyroid cancer (RAIR-DTC), Vandetanib showed less favorable progression-free survival (PFS) compared to Lenvatinib, which had a hazard ratio of 0.31 (0.20-0.49). Vandetanib ranked lower in overall survival (OS) than Apatinib.
• In medullary thyroid carcinoma (MTC), Vandetanib induced an objective response in 33.8% of patients, with disease progression occurring in 23.7%.
• Vandetanib was associated with a high incidence of grade 3 or higher adverse events in certain populations, including a 48.5% rate in MTC patients, with 44.7% of patients discontinuing treatment due to adverse events.
• Common adverse effects of Vandetanib included metabolic disorders (e.g., hypercholesterolemia, hypertriglyceridemia) and QTc prolongation, with gastrointestinal side effects and other manageable adverse events frequently observed across thyroid cancer types.
• Studies focused on adult cancer patients across different types of advanced cancers, including RAIR-DTC, hepatocellular carcinoma (HCC), and MTC, with subgroup analyses comparing treatment responses and survival outcomes specific to DTC, refractory thyroid cancer, and advanced MTC.